期刊文献+

反相高效液相色谱法测定小鼠肺组织中伏立康唑药物浓度 被引量:1

Determination of Voriconazole Concentration in Mice Lung by RP-HPLC
下载PDF
导出
摘要 目的建立用反相高效液相色谱法测定小鼠肺组织中伏立康唑浓度的方法。方法用Waters X-Terra Rp C18柱,柱温:25℃,样品室温度:20℃。流动相:乙腈-冰醋酸三乙胺缓冲液(41∶59),流速1.0 mL/min,检测波长为255 nm。酮康唑作为内标,肺组织匀浆经蛋白沉淀法处理后直接进样测定。结果肺组织匀浆伏立康唑药物浓度标准曲线在0.14~28.0μg/g(湿肺组织),回归方程:Y=0.1421X+0.025 7,r=0.999 7。平均提取回收率为102.58%±5.92%,平均方法回收率为102.23%±5.67%,高、中、低3个浓度的日内精密度RSD为1.30%~5.41%,日间精密度RSD为5.42%~5.68%。结论该方法具有良好的准确性和精密性,重现性好,适用于肺组织中伏立康唑药物浓度监测。 Objective To develop a method of reversed phase high performance liquid chromatography ( RP-HPLC ) for the determination of Voriconazole concentration in mice lung. Methods With Ketoconazole as the internal standard, voriconazole was extracted from mice lung samples by protein precipitation with acetonitrile. The X-Terra Rp C18 column (250 mm×4.6 ram, 5 μm) was selected to analyze the samples. The mobile phase consisted of aeetonitrile-glacial acetic acid triethylamine buffer solution (41:59). Flow rate was 1 mL/min at 25 ℃. The detection wave length was 255 nm. Results The standard curve was linear when voriconazole concentration in the range of 0.14- 28 μg/g (wet lung weight). The regression equation is 0.142 1×+0.025 7, r = 0.9997. The average extraction recovery rate was 102.58%±5.92%. The average analytical recovery rate was 102.23%±5.67%. The RSD of the between-day was 1.30%-5.41%. The RSD of the within-day was 5.42%-5.68%. Conclusion The established method was accurate, sensitive and stable. It is suitable for the determination of voriconazol concentration in mice lung.
出处 《今日药学》 CAS 2014年第7期489-491,共3页 Pharmacy Today
基金 广东省医院药学研究基金(编号:2013A14)
关键词 伏立康唑 反相高效液相色谱法 药物浓度 小鼠 voriconazol RP-HPLC drug concentration mice lung
  • 相关文献

参考文献3

二级参考文献14

  • 1沈银忠.伏立康唑的临床合理应用[J].世界临床药物,2009,30(12):715-720. 被引量:16
  • 2高洪志,梁宇光,林丽娜,胡锦超,刘泽源.2种伏立康唑片剂的人体生物等效性研究[J].中国新药杂志,2007,16(14):1133-1136. 被引量:7
  • 3Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring[J]. Antimicrob Agents Chemother, 2006, 50(4) : 1570.
  • 4Scott Lesley J, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections[J]. Drugs,2007,7(2):269.
  • 5Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/phannacodynamic profile of voficonazole [ J ]. Clin Pharmacokinet, 2006, 45 (7) : 649.
  • 6Trifilio S, Pennlck G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutie levels in hematopoietie stem cell transplant recipients[J]. Cancer,2007, 109(8) : 1532.
  • 7Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voricenazole concentrations and visual adverse events or liver function test abnormalities[J]. J Clini Pharmacol, 2006, 46(2):235.
  • 8Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring[ J]. Swiss Med Wkly, 2006, 136(45-46) :739.
  • 9Leveque D, Nivoix Y, Jehl F, et al. Clinical Pharmcokinetics of voriconazole[J]. Antimicrob Agents,2006,27(4) :274.
  • 10farms HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voficonazole in patients at risk of fungi1 infection: a dose escalation study[J].Clini Pharmacol, 2002, 42(4):395.

共引文献9

同被引文献3

  • 1McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a tour/he model[J]. Pharm Res, 2006,23:901 -911.
  • 2Tolman JA, Nelson NA, Bosselmann S, et al. Dose tolerability of chronically inhaled vorieonazole sol ution in rodents [ J ]. lnt J Pharm, 2009,379:25 -31.
  • 3Tolman JA, Wiederhold NP, McConville JT, et al. Inhaled voricon- azole for prevention of Invasive pulmonary aspergillosis [ J ]. Antimi- crob Agents Chemother, 2009,53:2613 - 2615.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部